OS Therapies Launches Subsidiary to Pursue ADC Joint Ventures, Prepares for FDA Submission

OS Therapies, a biotech company specializing in innovative cancer treatments, has announced the formation of a new subsidiary aimed at capitalizing on its antibody-drug conjugate (ADC) technology. This strategic move comes as the company prepares to seek FDA approval for its lead candidate in lung cancer and osteosarcoma.

New Subsidiary to Explore ADC Partnerships

OS Therapies has established OS Drug Conjugates, a subsidiary tasked with creating value from the company's tunable ADC and drug conjugate platforms. The new entity has initiated discussions with clinical-stage ADC therapeutics companies in the United States, China, and other jurisdictions to explore potential joint ventures.

The company's proprietary technology utilizes pH-sensitive silicon-based linkers to connect targeting antibodies with therapeutic moieties. This approach aims to leverage the lower pH levels found in tumors, potentially enhancing the selectivity of cancer treatments while minimizing damage to healthy cells.

OS Therapies envisions that successful joint ventures could be spun off into standalone publicly listed companies, with the parent company offering stock dividends to its shareholders. This strategy aligns with the growing market interest in combining therapeutic interventions to target specific cancer cells more effectively.

Advancing OST-HER2 Towards FDA Approval

While pursuing partnerships for its ADC technology, OS Therapies continues to prioritize the development of OST-HER2, its lead candidate. This innovative therapy uses a HER2-bioengineered form of Listeria monocytogenes to stimulate an immune response against HER2-expressing cancer cells.

Following a successful Phase 2 trial in lung cancer earlier this year, OS Therapies secured full intellectual property rights to OST-HER2 last month. The company is now preparing to submit an application for FDA approval in osteosarcoma, a form of bone cancer, during the second quarter of this year.

OS Therapies' CEO stated, "We believe our tunable drug conjugate platform could play an outsized role in creating combination therapies that will improve outcomes while reducing side effects." This sentiment underscores the company's commitment to developing more targeted and effective cancer treatments.